The nation's largest independent specialty pharmacy is now dispensing MAVYRET(TM) (glecaprevir and pibrentasvir).
FLINT, Mich., Aug. 17, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), is dispensing newly approved MAVYRET™ (glecaprevir and pibrentasvir) oral tablets for chronic hepatitis C virus infection.
To learn more about Diplomat's hepatitis program, visit diplomat.is/areas-of-excellence/hepatitis.
MAVYRET is indicated for patients with all major genotypes (1–6) of chronic hepatitis C virus infection without cirrhosis (liver disease) or with compensated cirrhosis. It is the first eight-week treatment duration approved for all genotypes in adult patients without cirrhosis who have not been previously treated.
MAVYRET is also indicated for adults with Genotype 1 infection who previously have been treated with a regimen containing an NS5A inhibitor or an NS3/4A protease inhibitor (but not both).
"We are proud to expand upon Diplomat's therapy offerings to patients who have been diagnosed with chronic hepatitis C," said Joel Saban, president of Diplomat. "This valuable treatment option gives more patients the possibility of a life without this serious disease."
More than 2.7 million Americans have hepatitis C, according to the Centers for Disease Control and Prevention. Hepatitis C infection becomes chronic in approximately 75–85 percent of cases.
MAVYRET is manufactured by AbbVie Inc. For full prescribing information, click here.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) is the nation's largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.
Kali Lucas, Public Relations Specialist
810.768.9580 | firstname.lastname@example.org
Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | email@example.com
View original content with multimedia:http://www.prnewswire.com/news-releases/diplomat-dispensing-mavyret-to-treat-chronic-hepatitis-c-300506166.html
SOURCE Diplomat Pharmacy, Inc.
© 2017 PR Newswire. All Rights Reserved.